Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.49 |
| ▸ | CDC25B | P30305 | 7/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.48 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.48 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.48 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.48 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.47 |
| ▸ | TACR2 | P21452 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10352583 | 0.99 | HTR1A (0.51) | HTR1APTPN1CDC25BNT5ESSTR1 | |
| SCHEMBL10400344 | 0.99 | HTR1A (0.51) | HTR1APTPN1CDC25BNT5ESSTR1 | |
| SCHEMBL16632204 | 0.92 | SSTR1 (0.49) | HTR1APTPN1CDC25BNT5ESSTR1 | |
| SCHEMBL16632203 | 0.92 | SSTR1 (0.49) | HTR1APTPN1CDC25BNT5ESSTR1 | |
| SCHEMBL16632115 | 0.92 | SSTR1 (0.49) | HTR1APTPN1CDC25BNT5ESSTR1 | |
| SCHEMBL16632114 | 0.92 | SSTR1 (0.49) | HTR1APTPN1CDC25BNT5ESSTR1 | |
| SCHEMBL18482846 | 0.91 | PDE4D (0.46) | HTR1APTPN1CDC25BNT5ESSTR1 | |
| SCHEMBL1770724 | 0.91 | SSTR1 (0.48) | HTR1APTPN1CDC25BNT5ESSTR1 | |
| SCHEMBL10400275 | 0.90 | HTR1A (0.49) | HTR1APTPN1CDC25BNT5ESSTR1 | |
| SCHEMBL10408388 | 0.90 | HTR1A (0.49) | HTR1APTPN1CDC25BNT5ESSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3966210-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2022-03-16 | — | — | EP | disclosed |
| US-10543223-B2 | Mannose derivatives useful for treating pathologies associated with adherent E. coli | ENTEROME (FR) | 2020-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10543223-B2 | Mannose derivatives useful for treating pathologies associated with adherent E. coli | FPR3, CCR3, RXFP3 | HTR1A 2229/4885PTPN1 3404/4885CDC25B 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.